Breaking News Instant updates and real-time market news.

RTRX

Retrophin

$22.50

-0.15 (-0.66%)

16:31
01/03/19
01/03
16:31
01/03/19
16:31

Retrophin names Eric Dube, Ph.D. President and CEO

Retrophin announced the appointment of Eric Dube, Ph.D. as president and CEO, effective January 4, 2019. Dr. Dube joins Retrophin from ViiV Healthcare, where he served as president of North America, and brings a successful track record of global leadership with significant expertise in delivering innovative therapies to address unmet patient needs. He will also serve as a member of Retrophin's Board of Directors. Dr. Dube succeeds Stephen Aselage who has served as CEO since 2014 and previously announced his planned retirement. Aselage will continue to serve as a member of the Retrophin Board of Directors.

  • 30

    Jun

RTRX Retrophin
$22.50

-0.15 (-0.66%)

11/19/18
NOMU
11/19/18
INITIATION
Target $57
NOMU
Buy
Retrophin initiated with a Buy at Nomura Instinet
Nomura Instinet analyst Christopher Marai started Retrophin with a Buy rating and $57 price target. The company's pipeline assets address high unmet needs and defined markets, and each could potentially double the company's revenue, Marai tells investors in a research note. He sees "de-risking" events beginning in 2019.
10/30/18
JEFF
10/30/18
INITIATION
Target $44
JEFF
Buy
Retrophin initiated with a Buy at Jefferies
Jefferies analyst Maury Raycroft started Retrophin with a Buy rating and $44 price target. The company has three Phase III programs and a "robust" commercial portfolio, Raycroft tells investors in a research note. Further, he believes the management team has demonstrated to be reliable with examples of execution.
08/17/18
ADAM
08/17/18
INITIATION
Target $36
ADAM
Buy
Retrophin initiated with a Buy at Canaccord
Canaccord analyst Michelle Gilson initiated Retrophin with a Buy rating citing what she views as an attractive valuation given the upside potential provided by the clinical stage pipeline. She sees limited downside risk but upside catalysts with POC data for CNSA-001 in early 2019 and Phase 3 FORT data in PKAN in the second half 2019. Gilson has a $36 price target on Retrophin shares.
04/19/18
HCWC
04/19/18
NO CHANGE
Target $182
HCWC
Buy
H.C. Wainwright reiterates Buy on Ligand after Novartis reports Q1
H.C. Wainwright analyst Joseph Pantginis says the Promacta franchise remains strong after Ligand Pharmaceuticals (LGND) partner Novartis (NVS) reported Q1 sales Promacta revenue of $257M. The analyst projects 2018 is the year that Promacta officially reaches blockbuster status, or $1B in sales. Further, he points out that Retrophin (RTRX), another Ligand partner, earlier this month announced that the first patient has been enrolled into the Phase 3 Duplex study using sparsentan to treat patients with focal segmental glomerulosclerosis. Pantginis is encouraged by the start of the Phase 3 saying it has the potential to lock in a fixed 9% royalty to Ligand, if approved. He currently project peak sales of $825M but feels the drug could reach blockbuster status based on its first-to-market status. Pantginis keeps a Buy rating on Ligand Pharmaceuticals with a $182 price target.

TODAY'S FREE FLY STORIES

PAG

Penske Automotive

$51.36

0.015 (0.03%)

17:13
11/13/19
11/13
17:13
11/13/19
17:13
Syndicate
Breaking Syndicate news story on Penske Automotive »

Penske Automotive files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

LLY

Eli Lilly

$112.85

-0.31 (-0.27%)

17:12
11/13/19
11/13
17:12
11/13/19
17:12
Hot Stocks
FDA committee says benefits of empagliflozin do not outweigh risks »

The FDA Endocrinologic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

PRTH

Priority Technology

$3.24

-0.03 (-0.92%)

17:08
11/13/19
11/13
17:08
11/13/19
17:08
Earnings
Priority Technology reports Q3 EPS (9c), one estimate (12c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPZ

Domino's Pizza

$279.24

1.185 (0.43%)

17:07
11/13/19
11/13
17:07
11/13/19
17:07
Hot Stocks
Domino's Pizza's Goldman sells 2,486 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 11

    Dec

  • 12

    Dec

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

17:04
11/13/19
11/13
17:04
11/13/19
17:04
Periodicals
WeWork reported $1.25B loss in Q3, NY Times reports »

WeWork (WE) lost $1.25B…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLYC

GlycoMimetics

$6.27

0.31 (5.20%)

17:02
11/13/19
11/13
17:02
11/13/19
17:02
Initiation
GlycoMimetics initiated  »

GlycoMimetics resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLK

BlackRock

$485.67

-1.24 (-0.25%)

17:00
11/13/19
11/13
17:00
11/13/19
17:00
Hot Stocks
BlackRock CFO sells nearly 4,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

ARVN

Arvinas

$28.35

1.85 (6.98%)

16:58
11/13/19
11/13
16:58
11/13/19
16:58
Initiation
Arvinas initiated  »

Arvinas initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FEYE

FireEye

$17.09

-0.04 (-0.23%)

16:57
11/13/19
11/13
16:57
11/13/19
16:57
Recommendations
FireEye analyst commentary  »

FireEye unique offering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

CSCO

Cisco

$48.44

0.06 (0.12%)

16:54
11/13/19
11/13
16:54
11/13/19
16:54
Hot Stocks
Cisco says cyber security is a top priority for customers »

Says innovation pipeline…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 09

    Dec

  • 10

    Dec

JPM

JPMorgan

$128.49

-0.65 (-0.50%)

16:54
11/13/19
11/13
16:54
11/13/19
16:54
Periodicals
JPMorgan's new HQ plan clears path for another NYC tower, Bloomberg says »

JPMorgan's plan to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 14

    Jan

SIBN

SI-Bone

$17.88

0.14 (0.79%)

16:53
11/13/19
11/13
16:53
11/13/19
16:53
Syndicate
Breaking Syndicate news story on SI-Bone »

SI-Bone files $200M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLI

RLI Corp.

$97.43

0.78 (0.81%)

16:52
11/13/19
11/13
16:52
11/13/19
16:52
Hot Stocks
RLI Corp. declares special cash dividend of $1.00 per share »

Payable on December 20 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CPA

Copa Holdings

$107.71

1.89 (1.79%)

16:52
11/13/19
11/13
16:52
11/13/19
16:52
Hot Stocks
Copa Holdings reports Q3 load factor up 1.4pts to 85.6% »

Copa Holdings reports Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 03

    Dec

XBIT

XBiotech

$11.42

0.18 (1.60%)

16:50
11/13/19
11/13
16:50
11/13/19
16:50
Recommendations
XBiotech analyst commentary  »

XBiotech price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AOBC

American Outdoor Brands

$7.90

0.22 (2.86%)

16:50
11/13/19
11/13
16:50
11/13/19
16:50
Hot Stocks
Breaking Hot Stocks news story on American Outdoor Brands »

American Outdoor Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPA

Copa Holdings

$107.71

1.89 (1.79%)

16:48
11/13/19
11/13
16:48
11/13/19
16:48
Earnings
Copa Holdings reports Q3 EPS $2.45, consensus $2.23 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 03

    Dec

IDXG

Interpace Diagnostics

$0.78

0.0001 (0.01%)

, CGIX

Cancer Genetics

$2.93

-0.2 (-6.39%)

16:48
11/13/19
11/13
16:48
11/13/19
16:48
Hot Stocks
Interpace Diagnostics changes name to Interpace Biosciences »

Interpace Diagnostics…

IDXG

Interpace Diagnostics

$0.78

0.0001 (0.01%)

CGIX

Cancer Genetics

$2.93

-0.2 (-6.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

  • 07

    Dec

TPTX

Turning Point Therapeutics

$48.68

0.84 (1.76%)

16:46
11/13/19
11/13
16:46
11/13/19
16:46
Initiation
Turning Point Therapeutics initiated  »

Turning Point…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBPO

China Biologic

$116.87

1.17 (1.01%)

16:46
11/13/19
11/13
16:46
11/13/19
16:46
Earnings
China Biologic raises FY19 income growth outlook to 11%-13% from 4%-6% »

The company is raising…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

CBPO

China Biologic

$116.87

1.17 (1.01%)

16:45
11/13/19
11/13
16:45
11/13/19
16:45
Earnings
China Biologic reports Q3 adjusted EPS $1.40, one estimate 88c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

IDXG

Interpace Diagnostics

$0.78

0.0001 (0.01%)

16:45
11/13/19
11/13
16:45
11/13/19
16:45
Earnings
Breaking Earnings news story on Interpace Diagnostics »

Interpace Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

CSCO

Cisco

$48.44

0.06 (0.12%)

16:45
11/13/19
11/13
16:45
11/13/19
16:45
Hot Stocks
Breaking Hot Stocks news story on Cisco »

Cisco down about 5% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 09

    Dec

  • 10

    Dec

IDXG

Interpace Diagnostics

$0.78

0.0001 (0.01%)

16:44
11/13/19
11/13
16:44
11/13/19
16:44
Earnings
Interpace Diagnostics lowers 2019 revenue view to $28M-$32M from $33M-$36M »

Consensus for 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

IDXG

Interpace Diagnostics

$0.78

0.0001 (0.01%)

16:43
11/13/19
11/13
16:43
11/13/19
16:43
Earnings
Interpace Diagnostics reports Q3 EPS (19c), consensus (19c) »

Reports Q3 revenue $7.7M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.